The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Animal studies of Anadys Pharmaceutical's new non-nucleoside Hepatitis C inhibitor have delivered some hopeful results. Although the subjects were primates, ANA598's demonstration of rapid viral load decline, favorable pharmacokinetics, safety, and tolerability profiles support its continued development.
Continue reading »The importance of learning your Hepatitis C genotype is crucial in determining a recommended treatment plan. As researchers discover yet another genotype, prescribed medicines will become increasingly tailored to each individual's Hepatitis C infection.
Continue reading »A substantial, five-year study confirms that when it comes to treating Hepatitis C, one size does not fit all. When combined with pegylated interferon, researchers discovered basing the dosage of ribavirin on a patient's weight could yield better results than giving all participants a flat dosage of ribavirin. In addition, the weight-based ribavirin dosage demonstrated a clear advantage to African Americans with Hepatitis C, whose outcomes has previously lagged behind those of Caucasian patients.
Continue reading »Collaboration between French and American researchers has uncovered a possible genetic link among those who progress from cirrhosis to liver cancer. If this genetic variation is confirmed to be behind the development of hepatocellular carcinoma, this gene will be evaluated in cirrhotic patients and may be the basis for future therapies.
Continue reading »By eating a hot breakfast in the winter, a person with Hepatitis C can begin their day with a healthy start. Although most hot breakfast foods are not good for you, eating oatmeal in the morning offers a number of liver-specific health benefits.
Continue reading »While most doctors are vigilant about disease transmission prevention, Long Island physician Dr. Harvey Finkelstein violated this vigilance when he reused syringes on his clientele. Although nearly impossible to determine where the infection originated, twelve more of Finkelstein's patients have just tested positive for Hepatitis.
Continue reading »GI-5005 Tarmogen is under consideration as the third drug in a cocktail for treating chronic Hepatitis C. In an international Phase II trial just getting underway, GI-5005 will be paired with the current standard of therapy - pegylated interferon and ribavirin.
Continue reading »Already approved in the Russian Federation for treating Hepatitis B and C, NOV-205 has just demonstrated its safety in a U.S. Phase 1b trial. As we progress into 2008, look for reports on the efficacy of this drug.
Continue reading »American and Canadian scientists unite in studying a novel approach for reducing the scope of Hepatitis C infection. Their isolation and injection of specific antibodies into liver tissue demonstrates potential in preventing or slowing the Hepatitis C virus.
Continue reading »In collaboration with health centers across the globe, researchers at Duke University Medical Center are excited about a once daily pill for increasing blood platelet counts. To help patients complete antiviral therapy, the researchers found that eltrombopag effectively raises blood platelets in those with low platelet counts and cirrhosis of the liver due to Hepatitis C.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
